# Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

> **NCT00699192** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 965 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Amlodipine 5 mg
- **DRUG:** Valsartan 80 mg
- **DRUG:** Valsartan 40 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00699192
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 965 (ACTUAL)
- **Last updated:** 2011-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699192, "Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00699192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*